Meropenem Hikma

Meropenem, the active ingredient in Meropenem Hikma, is a carbapenem presented as a sterile powder for intravenous use. It treats severe bacterial infections in hospitalized adults and children, including intra‑abdominal, urinary, respiratory, bloodstream, and skin infections.

GNH USA supplies Meropenem Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides regulatory‑approved batches to meet global demand for critical care settings.

Meropenem is a broad‑spectrum carbapenem antibiotic used for serious infections affecting various organ systems.

- Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: provides rapid bacterial clearance and symptom resolution. - Hospital‑acquired pneumonia: improves lung infection outcomes in ventilated patients. - Septicemia: offers broad coverage against Gram‑negative and Gram‑positive pathogens in bloodstream infections. - Skin and soft tissue infections: facilitates healing by eliminating resistant bacterial strains.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that may be self‑limiting. - Rash: skin erythema or pruritus. - Infusion site phlebitis: pain or redness at the IV site. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Anaphylaxis: acute allergic reaction requiring immediate medical attention. - Severe neutropenia: marked reduction in white blood cells. - Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for adverse events.

- Renal function: adjust dose in patients with impaired clearance. - Hypersensitivity: avoid in individuals with known carbapenem or beta‑lactam allergy. - Pregnancy: category B; use only when benefits outweigh potential risks. - Concomitant valproic acid: monitor for reduced antiepileptic levels. - Monitoring: observe for neurologic changes, especially seizures, during high‑dose therapy. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Meropenem can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Valproic acid: meropenem markedly reduces serum valproate concentrations, risking seizure breakthrough. - Probenecid: may increase meropenem plasma levels, heightening toxicity. - High‑dose aminoglycosides: combined nephrotoxic potential.

Moderate Interactions (Monitor Closely): - Loop diuretics: electrolyte shifts may predispose to seizures. - Other nephrotoxic agents (e.g., vancomycin): monitor renal function. - Oral contraceptives: possible reduction in contraceptive effectiveness; advise alternative birth control.